Author: Ian Mason

New research has flagged the value of early aggressive antidepressant treatment in adolescents who have failed to respond to SSRIs.

In less than six years, GlaxoSmithKline has moved from being “virtually nowhere” in biopharmaceuticals to becoming a player in this increasingly important area of drug development.

The International Iberian Nanotechnology Laboratory was formally opened in Braga, Portugal at the weekend and the massive complex – which covers 26,000 square metres and will house 200 scientists – is scouting for pharma and biotech partners for cutting-edge nanomedicine projects.

Two important milestones for Raptiva (efalizumab) – Merck Serono’s biological therapy for psoriasis – were reached this weekend.

Patients in many countries are being denied effective new biologic therapies for psoriasis due to old fashioned clinical thinking and needlessly complex prescribing and reimbursement restrictions, say leading dermatologists.